In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Nuvectis Pharma (NVCT – Research Report), with a price target of $21.00. The company’s shares closed yesterday at $8.35.
According to TipRanks, Pantginis is an analyst with an average return of -20.0% and a 26.30% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Humanigen, Astria Therapeutics, and Celldex.
Currently, the analyst consensus on Nuvectis Pharma is a Moderate Buy with an average price target of $21.00.
See today’s best-performing stocks on TipRanks >>
Based on Nuvectis Pharma’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $3.57 million. In comparison, last year the company had a GAAP net loss of $5.94 million
Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NVCT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. Its pipeline products include NXP800, NXP900.
Read More on NVCT:
- Analysts’ Top Healthcare Picks: Zealand Pharma (ZEAL), POINT Biopharma Global (PNT)
- August’s Top Malware: Emotet Knocked off Top Spot by FormBook while GuLoader and Joker Disrupt the Index
- Revive Therapeutics Announces Submission of Amended Phase 3 COVID-19 Study Protocol to FDA
- LMP Automotive Holdings, Inc. Announces its Affiliates Entered into All-Cash Sale Agreements for its Remaining Dealership and its Associated Real Estate
- Coda Octopus Group Reports Fiscal 2022 Third Quarter and Nine-Month Period Financial Results
